Johnson & Johnson subsidiary McNeil-PPC reached a $33 million settlement with 43 states to resolve allegations the company sold contaminated drugs and used inappropriate marketing practices, reports Pittsburgh Post-Gazette.
The lawsuit alleges McNeil illegally promoted its medications by falsely claiming they were manufactured in compliance with federal regulations, according to the report.
McNeil recalled millions of drugs manufactured between 2009 and 2011 at its Fort Washington, Penn.-based plant, following reports of abnormal odors and foreign particles in its liquid medications. The drugs were sold under the following brand names: Tylenol, Motrin, Benadryl, St. Joseph Aspirin, Sudafed, Pepcid, Mylanta, Rolaids and Zyrtec.
In a Wednesday statement, Johnson & Johnson said it was "pleased" to finalize the settlement, reports Chicago Tribune. The company noted the recalls were voluntary and said McNeil-PPC admits no wrongdoing through the settlement, according to the report.
More articles on supply chain:
Biogen offshoot to acquire rare disease biotech for $400M: 4 things to know
Why FDA's newest approval paves the way for precision medicine
Supply chain tip of the day: How pharmacy can drive revenue for a health system post-merger